International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3, Supplement , Pages S58-S63, 1 March 2010

Radiotherapy Dose–Volume Effects on Salivary Gland Function

  • Joseph O. Deasy, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Washington University School of Medicine and Alvin J. Siteman Cancer Center, St. Louis, MO
    • Corresponding Author InformationReprint requests to: Joseph O. Deasy, Ph.D., Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Pl., St. Louis, MO 63110. Tel: (314) 362-1420; Fax: (314) 362-8521
  • ,
  • Vitali Moiseenko, Ph.D.

      Affiliations

    • Department of Medical Physics, British Columbia Cancer Agency–Vancouver Cancer Center, Vancouver, BC, Canada
  • ,
  • Lawrence Marks, M.D.

      Affiliations

    • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
  • ,
  • K.S. Clifford Chao, M.D.

      Affiliations

    • Department of Radiation Oncology, Columbia School of Medicine, New York, NY
  • ,
  • Jiho Nam, Ph.D.

      Affiliations

    • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
  • ,
  • Avraham Eisbruch, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI

Received 6 February 2009; received in revised form 8 June 2009; accepted 12 June 2009.

Publications relating parotid dose–volume characteristics to radiotherapy-induced salivary toxicity were reviewed. Late salivary dysfunction has been correlated to the mean parotid gland dose, with recovery occurring with time. Severe xerostomia (defined as long-term salivary function of <25% of baseline) is usually avoided if at least one parotid gland is spared to a mean dose of less than ≈20 Gy or if both glands are spared to less than ≈25 Gy (mean dose). For complex, partial-volume RT patterns (e.g., intensity-modulated radiotherapy), each parotid mean dose should be kept as low as possible, consistent with the desired clinical target volume coverage. A lower parotid mean dose usually results in better function. Submandibular gland sparing also significantly decreases the risk of xerostomia. The currently available predictive models are imprecise, and additional study is required to identify more accurate models of xerostomia risk.

Xerostomia, salivary parotid glands, submandibular salivary glands, radiotherapy, dose–volume effects

 

 Partially funded by National Institutes of Health Grant R01 CA85181 (to J. O. Deasy) and Grant CA69579 (L. B. Marks) and by the American Association of Medical Physicists and the American Society of Therapeutic Radiology.

 Conflict of interest: none.

PII: S0360-3016(09)03289-1

doi:10.1016/j.ijrobp.2009.06.090

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 3, Supplement , Pages S58-S63, 1 March 2010